Fig. 3: Time-to-event plot showing the time between treatment initiation and the development of irAEs in seven cancer types. | npj Precision Oncology

Fig. 3: Time-to-event plot showing the time between treatment initiation and the development of irAEs in seven cancer types.

From: Real-world data analyses unveiled the immune-related adverse effects of immune checkpoint inhibitors across cancer types

Fig. 3

A Melanoma. B Renal cancer. C Head and neck cancer. D Squamous cell carcinoma. E Basal cell carcinoma. F Brain cancer. G Lung cancer. The comparisons between chemotherapy with pembrolizumab, nivolumab, and all immune checkpoint inhibitors combined are shown in the three columns respectively. The top panel is the time-to-event plot for all irAEs, with a log-rank test p-value reported on the top right corner for both matched and unmatched samples. Each tick represents 50 censored patients. The curves are truncated in the 15th month after treatment initiation for better visualization.

Back to article page